Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis

[1] Roila F(2016)2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol 27 v119-v133

[2] Molassiotis A(2002)Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87 118-128

[3] Herrstedt J(2017)Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment Journal of Clinical Oncology 35 LBA2-LBA2

[4] Aapro M(2017)Hospitalization costs for nausea and vomiting: A savings opportunity Journal of Clinical Oncology 35 155-155

[5] Gralla RJ(2010)Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Supportive Care in Cancer 19 131-140

[6] Bruera E(2016)Antiemetics: American Society of Clinical Oncology focused Guideline Update J Clin Oncol 34 381-386

[7] Clark-Snow RA(2014)International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice Eur J Pharmacol 722 197-202

[8] Dupuis LL(1998)Initial control of chemotherapy-induced nausea and vomiting in patient quality of life Oncology (Williston Park, NY) 12 32-37

[9] Einhorn LH(2014)Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study Ann Oncol 25 1340-1346

[10] Feyer P(2016)NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron Supportive Care in Cancer 25 1127-1135

[1] Roila F(2016)2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol 27 v119-v133

[2] Molassiotis A(2002)Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87 118-128

[3] Herrstedt J(2017)Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment Journal of Clinical Oncology 35 LBA2-LBA2

[4] Aapro M(2017)Hospitalization costs for nausea and vomiting: A savings opportunity Journal of Clinical Oncology 35 155-155

[5] Gralla RJ(2010)Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Supportive Care in Cancer 19 131-140

[6] Bruera E(2016)Antiemetics: American Society of Clinical Oncology focused Guideline Update J Clin Oncol 34 381-386

[7] Clark-Snow RA(2014)International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice Eur J Pharmacol 722 197-202

[8] Dupuis LL(1998)Initial control of chemotherapy-induced nausea and vomiting in patient quality of life Oncology (Williston Park, NY) 12 32-37

[9] Einhorn LH(2014)Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study Ann Oncol 25 1340-1346

[10] Feyer P(2016)NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron Supportive Care in Cancer 25 1127-1135